Krüppel‐like factor 4 promotes c‐Met amplification‐mediated gefitinib resistance in non‐small‐cell lung cancer

Gefitinib has been widely used in the first‐line treatment of advanced EGFR‐mutated non‐small‐cell lung cancer (NSCLC). However, many NSCLC patients will acquire resistance to gefitinib after 9‐14 months of treatment. This study revealed that Krüppel‐like factor 4 (KLF4) contributes to the formation...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Wei, Xie, Qianyi, Liu, Suo, Ji, Ying, Li, Chunyun, Wang, Chunle, Jin, Longyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989843/
https://www.ncbi.nlm.nih.gov/pubmed/29624806
http://dx.doi.org/10.1111/cas.13601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989843/
https://www.ncbi.nlm.nih.gov/pubmed/29624806
http://dx.doi.org/10.1111/cas.13601

Ejemplares similares